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ABSTRACT
Introduction Approximately 38% of haemodialysis
patients carry Staphylococcus aureus in their noses, and
carriers have a nearly four-fold increased risk of S. aureus
access-related bloodstream infections (BSIs) compared
with non-carriers. Our objective is to determine the
clinical efficacy and effectiveness of a novel intervention
using nasal povidone-iodine (PVI) to prevent BSIs among
patients in haemodialysis units. We will survey patients
and conduct qualitative interviews with healthcare workers
to identify barriers and facilitators to implementing the
intervention.
Methods and analysis We will perform an open-label,
stepped-wedge cluster randomised trial to assess the
effectiveness of nasal PVI compared with standard care.
Sixteen outpatient haemodialysis units will participate
in the study. The 3-year trial period will be divided into a
4-month baseline period and eight additional 4-month time
blocks. The primary outcome of the study will be S. aureus
BSI, defined as a S. aureus positive blood culture collected
in the outpatient setting or within one calendar day
after a hospital admission. The study team will evaluate
characteristics of individual patients and the clusters
by exposure status (control or intervention) to assess
the balance between groups, and calculate descriptive
statistics such as average responses separately for control
and intervention survey questions.
Ethics and dissemination This study has received IRB
approval from all study sites. A Data Safety and Monitoring
Board will monitor this multicentre clinical trial. We will
present our results at international meetings. The study
team will publish findings in peer-reviewed journals and
make each accepted peer-reviewed manuscript publicly
available.
Trial registration number NCT04210505.

For numbered affiliations see
end of article.
Correspondence to
Dr Ana-Monica Racila;
ana-monica-racila@uiowa.e du

INTRODUCTION
Patients on chronic haemodialysis are an ideal
target population in whom to implement

Strengths and limitations of this study
►► Novel intervention targets a modifiable risk factor

for Staphylococcus aureus bloodstream infections in
patients on haemodialysis.
►► Stepped-wedge cluster randomised trial design allows units to serve as their own controls and as a
control for other units, thus limiting selection bias
and imbalance among the intervention and control
units.
►► Nasal povidone-iodine suppresses bacteria for only
12–24 hours and must be reapplied before each
procedure.

interventions to decrease rates of Staphylococcus
aureus infections. More than 400 000 patients
received haemodialysis in 2018, and the majority
of these patients received in-centre haemodialysis.1 Between 2005 and 2008, 43% of patients
on haemodialysis tracked in the US Renal Data
System were hospitalised for infection-
related
diagnoses.2 Approximately 30% of bloodstream
infections (BSIs) among patients on haemodialysis are caused by S. aureus3 4 and these infections
cause considerable morbidity5–8 and mortality.7 9
Several factors increase the risk for S. aureus
infections among patients on haemodialysis.
First, a substantial proportion (38%) of these
patients carry S. aureus in their noses, and
carriers have a nearly four-fold increased risk
of S. aureus access-related BSI compared with
non-carriers.10 Second, these patients have
impaired immune function, which makes
them more susceptible to infection.11 Third,
S. aureus can colonise the skin on patients’
vascular access sites (arteriovenous grafts or
fistulae) and this organism can be introduced

Racila A-M, et al. BMJ Open 2021;11:e048830. doi:10.1136/bmjopen-2021-048830

1

BMJ Open: first published as 10.1136/bmjopen-2021-048830 on 3 December 2021. Downloaded from http://bmjopen.bmj.com/ on December 22, 2021 at Washington University School of
Medicine Library &. Protected by copyright.

Open access

into bloodstream when the skin is punctured or dialysis
catheters are accessed.12–15 Fourth, the S. aureus colonising one patient can be transmitted to other patients
in the same haemodialysis unit. We previously found that
87% of patients on dialysis who carried S. aureus in their
noses and on their hands carried the same strains at both
sites, suggesting transmission from the patients’ noses
to their skin.16 The S. aureus strains can then be transmitted from patient-to-patient in a haemodialysis unit via
direct contact between patients and healthcare workers’
(HCWs) hands and indirectly by contaminated furniture
and equipment.17 Unlike many other risk factors for BSI
in this patient population (eg, comorbidities), S. aureus
nasal carriage is modifiable and thus our intervention
could substantially benefit this population.2 3 18
To date, studies that evaluated nasal decolonisation of
patients on haemodialysis assessed the efficacy of intranasal mupirocin ointment for decolonisation and infection prevention.19 However, few dialysis centres have
included mupirocin decolonisation as a standard practice due to implementation barriers such as concern for
mupirocin resistance and complicated protocols.19–22
Povidone-iodine (PVI) has been used as an antiseptic in
the healthcare setting for decades and PVI resistance has
not been found.23 24 Thus, nasal PVI can be given to all
patients who are not allergic to iodine regardless of their
colonisation status. 5% PVI (w/w (0.5% available iodine)
USP) is available under the US Food and Drug Administration (FDA) Final Rule.25 Our objective is to perform
a multicentre stepped-
wedge cluster randomised trial
(CRT) to determine the clinical efficacy and effectiveness
of a novel intervention using nasal PVI to prevent BSIs
among patients on hamodialysis. We will survey patients
and conduct qualitative interviews with HCWs to identify
barriers and facilitators to implementing the intervention.
Objective 1
Conduct a multicentre, stepped-wedge CRT to determine
whether nasal PVI decolonisation reduces infections
among patients on haemodialysis.

patients on haemodialysis, to qualitatively evaluate the
implementation of this intervention, and to measure
HCW and patient satisfaction with PVI. We will randomly
assign when haemodialysis units (clusters) will cross over
from the control group to the intervention group such
that all units will eventually receive the intervention.26
The control group will consist of standard care as regulated by US Centers for Medicare and Medicaid Services
(CMS). We will include new patients who begin haemodialysis and stop patient follow-up when a patient is no
longer on haemodialysis (eg, recovery of kidney function,
kidney transplantation or death).2
Sixteen outpatient haemodialysis units will participate
in the study. The 3-year trial period will be divided into
a 4-month baseline period and eight additional 4-month
time blocks (table 1). All units will begin in the control
condition (C; no intervention). Two units (a unit pair)
will be added to the intervention (I) in a stepwise fashion
at the beginning of the eight additional time blocks.26
Study setting and participants
The proposed research will be performed at outpatient
haemodialysis units affiliated with five US academic
medical centres in the Southeast, Midwest and Northeast.
This multicentre study of geographically diverse hospital
systems and their patient populations will improve the
external validity of our study. We have confirmed that none
of the study sites currently perform nasal decolonisation.
We will enrol patients if they are 18 years or older
and receiving outpatient chronic haemodialysis (three
sessions a week). We will exclude patients receiving
peritoneal dialysis or home haemodialysis, patients with
documented or verbalised sensitivity or allergy to iodine
or iodine-based contrast, patients with known pregnancy,
and patients on treatment for bacterial infection. We will
enroll adult HCWs working at any of the 16 haemodialysis
units who are willing to participate in the semistructured
interviews.

METHODS AND ANALYSIS
Study design
We will perform an open-label, stepped-wedge CRT to
assess the effectiveness of nasal PVI compared with standard care. Our objectives are to evaluate whether using
intranasal PVI will reduce rates of S. aureus BSI among

Screening and recruitment
Research team members at each dialysis centre will
identify patients that meet inclusion criteria and will
discuss the study with patients during a haemodialysis
session, while ensuring that patient care is not delayed or
disrupted. This study was approved with a waiver of signed
consent, as the study is deemed low-risk and patients may
have trouble writing while receiving haemodialysis. Thus,
patients who verbally agree to the informed consent will
be included in the study.
Two research team anthropologists will schedule and
conduct semistructured interviews with 5–10 HCW at haemodialysis units across the five centres to examine the contextual
factors that influence adoption of nasal PVI decolonisation.
The anthropologists will ask each unit’s medical director for
permission to interview staff and for the names of potential
interviewees. The anthropologists will invite potential interviewees—the nurse manager, a physician, nurses, nursing
assistants or technicians—to participate.
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Objective 2
Survey patients to assess their satisfaction with nasal PVI
decolonisation, assess PVI’s role in patient activation
around their own health before and after PVI use, and
identify barriers and facilitators to implementation.
Objective 3
Examine HCW satisfaction with implementation of nasal
PVI decolonisation and assess barriers and facilitators to
the process via qualitative interviews and site visits.
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Stepped-wedge cluster randomised trial study design
Table 1
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This study has received institutional IRB approval from the
University of Iowa and site-specific IRB approval, including
waiver of documentation of informed consent. We will
offer participants the opportunity to talk with the treating
physician or their family member before consenting. Study
participation will not influence the standard of care subjects
would otherwise receive for their disease process. To minimise risks, all subjects will be carefully prescreened to identify any factors that could contribute to increased risk. We
will capture adherence to the intervention during repeated
site visits and patient surveys administered throughout the
intervention period, and we will record patient drop-out. We
will store all confidential information in locked offices and
store electronic data on password-protected computers only
available to study team members. Participants will receive
study team members’ contact information.
Sample size and power
We used the method described by Hussey and Hughes
to calculate the sample size and the study’s power.27 As
described above, the stepped-
wedge study will last 36
months (time points) with data collected monthly from
16 sites (clusters). After the baseline period, two sites
will transition to the intervention at the start of each
subsequent 4-
month block. Our pilot data suggested
that approximately 1825 patients will receive haemodialysis at any given time across all sites, with approximately
100 patients per site per time point (N). We estimated
the between site variability as τ2=0.01. Given that 3% of
patients who received haemodialysis at our study sites
during 2016 acquired S. aureus BSI, we estimated the
within-site variability to be 0.00029. Thus, we estimated
that we will have 98% power to see a change in the rate
of S. aureus BSI from 3% to 2% (absolute difference=1%,
OR=0.66). This difference is more conservative than the
difference seen in prior mupirocin decolonisation studies
among patients on haemodialysis (OR=0.32–0.51).19 Our
pilot data indicated that 30% of patients on haemodialysis
at our study sites were dialyzed through central venous
catheters, 5% of whom acquired S. aureus BSI in 2016.
Given this information, we estimated that a subset analysis of patients dialyzed through catheters will have 99%
power to identify a decrease in infections from 5% to 2%
(absolute difference=3%, OR=0.40).
Randomisation
We paired dialysis units into 2-unit blocks according to
two rules: (1) The dialysis units in a pair were not within
the same geographical region and (2) The approximate
total monthly unique patients in a given unit block would
be approximately 150 patients. Two study team members
independently created the dialysis unit blocks and they
minimised the variation from the ideal unit block size
when their pairings disagreed. After we created the
two-unit block pairs, we used the sample function in R
without replacement to randomise the order in which the
pairs would enter the intervention phase. Each unit block
had the same probability of selection. We stored the final
3
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Table 2 Schedule of events table for both haemodialysis and healthcare worker visits
Event

Visit 1 Visit 2

Visit 3

Visit 4

Each dialysis
appointment

Every 6
months*

Once

Review of inclusion/exclusion criteria and lab results to
confirm subject eligibility
Testing for Staphylococcus aureus nasal carriage

X

X

 

 

 

 

 

X

 

 

 

 

X

 

Preintervention Survey

X

 

 

 

 

 

 

Povidone-iodine administration

 

X

 

 

X

 

 

Intervention Survey
Healthcare worker interview

 
 

 
 

X
 

X
 

 
 

 
 

 
X

*A study member will obtain the nasal swabs during the subject’s dialysis sessions. This is in addition to the povidone-iodine administration.

randomisation in a password-protected file. Only the two
team members who performed the randomisation and
3M, which must coordinate delivery of the product to the
participating sites in accordance with the project timeline,
have access to that file. We will notify sites 4 months before
their planned intervention start date. The research team
is well connected with all sites and will prevent premature
implementation of the intervention.
Intervention
Events and procedures for haemodialysis subjects will
occur over four research visits (table 2). Research
personnel will visit the dialysis centres four times over the
study period.
Visit 1
Approximately a month before a dialysis unit is scheduled
to begin the intervention, a study team member will visit
the dialysis unit. During the visit, the study team member
will describe the study, obtain verbal informed consent
from patients present, and administer the preintervention (control) survey to all patients on haemodialysis who
agree to participate. A study team member also will swab
participants’ noses to identify patients who carry S. aureus
at baseline.
Visit 2
When a dialysis unit is scheduled to begin the intervention, study personnel will obtain verbal informed consent
from patients present and give each participating patient
their first disposable, single-use bottles of PVI, 4 applicators and illustrated instructions for use. Participating
patients will apply PVI at each haemodialysis appointment. Patients will be encouraged to apply the PVI to
their own noses, but they can also ask a nurse or technician for assistance. Patients will also have the option to
apply PVI at home.

of PVI approximately 1 month after the intervention has
started.
Visit 4
Approximately 5 months after the beginning of the intervention and after obtaining verbal informed consent
from the patient, a study team member will administer
the second intervention survey. The two intervention
surveys will ask the same questions and will be performed
in the same manner. The results of the control period
survey and the two intervention period surveys for each
patient can be linked together.
Staphylococcus aureus point prevalence studies
Each haemodialysis unit will collect nasal swabs from
each participating haemodialysis patient’s nose during
the baseline period and twice per year over the 3-year
study period (total of six times including baseline) we will
collect nasal swabs to determine S. aureus colonisation
status.
HCW interview
Two members of the research team will conduct semistructured in-person interviews with staff during site visits. The
semistructured interviews will include open-
ended questions to explore domains including barriers and facilitators
to implementing the intervention, provider and patient
compliance with PVI decolonisation, and the acceptability
and feasibility of PVI decolonisation. Interviews will be
audiorecorded with the HCWs’ permission and transcribed.

Visit 3
After a dialysis session has begun and after obtaining
verbal informed consent from the patient, a study team
member will administer the first intervention survey to the
patient. This intervention survey will assess acceptability

Outcomes and data collection
Primary outcome
The primary outcome of the study will be S. aureus BSI,
defined as a S. aureus positive blood culture collected in
the outpatient setting or within one calendar day after
a hospital admission. This outcome is collected every
month by dialysis staff or infection prevention staff at
each hospital system in accordance with The US Centers
for Disease Control and Prevention’s National Healthcare
Safety Network and the US CMS requirements. These
data will be shared with the study team and validated via
chart review.
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Table 3 Definitions of secondary outcomes (CDC NHSN definitions)
Bloodstream infection (BSI)
Access related bloodstream infection (ARBSI)

A positive blood specimen collected in the outpatient setting or within one
calendar day after a hospital admission.
A bloodstream infection with the suspected source reported as the vascular
access or uncertain.

Staphylococcus aureus ARBSI

An ARBSI in which the blood specimen was determined to be S. aureus.

Local access site infection

Pus, redness or increased swelling at the vascular access site when an ARBSI
is not present.

S aureus local access site infection

Pus, redness or increased swelling at the vascular access site when an ARBSI
is not present but with positive culture for S. aureus.
An S. aureus positive blood specimen collected in the outpatient setting or
within one calendar day after a hospital admission from patients participating
in the intervention.

S aureus BSI among intervention participants

CDC NHSN, Centres for Disease Control and Prevention’s National Healthcare Safety Network.

Secondary and additional outcomes
Definitions of secondary outcomes are presented in
table 3 with additional evaluated outcomes presented in
table 4.
During each site’s intervention period, a member of
the study team will swab each participant’s nares during
their haemodialysis session after the patient applies PVI
to determine if patients are colonised with S. aureus after
applying PVI and during the at-
risk period. S. aureus
isolates will be tested for methicillin-
susceptibility and
the research team will perform pulsed field gel electrophoresis on all nasal isolates and if available, bloodstream isolates to assess whether serial isolates from the
same patient are related, whether isolates from different
patients in the same dialysis unit are related, and whether
nasal isolates and infecting isolates from the same patient
are identical. A sample of S. aureus isolates will be evaluated using whole genome sequencing. Laboratory testing
will occur in a single laboratory using standardised
methodology.
Statistical and ethnographic analysis
Objective 1
The study team will evaluate characteristics of individual
patients and the clusters by exposure status (control or
intervention) to assess the balance between groups. As
most participants will take part in both settings, paired
t-tests, McNemar’s test and repeated measures analysis of
variance will be used as appropriate. The overall proportion of unique patients in the control group who acquire

infections compared with the intervention group will be
assessed via McNemar’s Test.
In the primary analysis, the study team will use a generalised linear mixed model (GLMM) with a logit link function to perform an analysis at the individual patient level
evaluating the association between nasal PVI and S. aureus
BSI. The model will include step and intervention indicators as fixed effects and a random intercept for cluster
to account for hospital dependence. The study team will
statistically adjust for important confounding variables,
such as dialysis access type. The study team will perform an
intention-to-treat analysis, assuming all patients received
nasal PVI during the intervention periods. Patients who
stop using PVI will be included in the study and evaluated
for outcomes in this intention-to-treat analysis. Reasons
for study ‘drop-out’ such as death or renal transplant are
not related to the intervention. However, the study team
will model time to drop-out to characterise this patient
population. An analysis will also be performed among
patients who met the inclusion criteria, agreed to participate in the study, and received at least one dose of PVI.
Because patients who receive haemodialysis through
central venous catheters are at the highest risk of infection, the study team use the GLMM methods described
above to evaluate the association between nasal PVI and
S. aureus BSI stratified by dialysis access type. The study
team will also perform exploratory analyses to assess
the effect of rural vs urban haemodialysis units and the
effect of nasal PVI on methicillin-resistant S. aureus and

Table 4 Additional outcomes evaluated
Patient satisfaction with nasal PVI
Healthcare worker satisfaction with intervention
Staphylococcus aureus colonisation

Barriers and facilitators to the intervention collected from patients through
qualitative surveys.
Barriers and facilitators to the intervention collected through qualitative
interviews with healthcare workers.
The presence of S. aureus in the nares.

PVI, povidone-iodine.
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methicillin-susceptible S. aureus BSIs separately. Finally,
the study team will evaluate the effect of nasal PVI on the
secondary outcomes: all BSI caused by any pathogen, all
BSI caused by any pathogen, local access site infection
and vascular access infection. The study team will use SAS
V.9.4 for all analyses.

request. In year 5 of the study, we will present our results
at international meetings. We will publish our findings
in peer-reviewed journals and make each peer-reviewed
accepted manuscript publicly available.

Ethics and dissemination
The risk to patients is low in this study; however, a data
and safety monitoring board (DSMB) will oversee this
study. The DSMB will be made up of clinical, biostatistical, infectious disease and renal disease experts who
are approved by the Agency for Health Research and
Quality. Occurrence of adverse events will be monitored
throughout the trial by surveys and the study team, and
will cover all randomised subjects. Rare allergy to PVI will
be treated by haemodialysis staff if needed. This is a phase
IV study of an antiseptic that is available under the FDA
Final Rule (Federal Register December 20, 2017).25 Any
potential side effects from PVI will be captured through
patient surveys. To protect confidentiality, we will assign
each subject a study ID. All electronic files are stored on
password-protected computers that are connected to a
secured shared drive. Nasal swabs will be labelled with
a coding descriptor, and no PHI will be collected from
the lab. The isolates will be discarded after the results
are finalised. Only the PI, data analysts, statistician and
the DSMB will have access to the final trial data set. Site
principal investigators will have direct access to their own
site’s data sets, and will have access to other sites’ data by

DISCUSSION
Prior studies have found that nasal decolonisation with
mupirocin reduced infection rates among patients on
haemodialysis.13 16 19 For example, Weiner et al demonstrated that nasal mupirocin was associated with a
fourfold reduction in S. aureus BSIs in this patient population.28 However, consistent use of mupirocin can lead
to mupirocin-resistant S. aureus.13 A meta-analysis found
that decolonisation with mupirocin was associated with
a 59% reduction in S. aureus infections among dialysis
patients, but up to 10% of patients who used mupirocin
become colonised with a mupirocin-resistant S. aureus
strain.19 Given that mupirocin prophylaxis can increase
the frequency of mupirocin-resistant S. aureus isolates,
and that the mupirocin decolonisation protocol is often
difficult to implement, most haemodialysis units do not
routinely decolonise patients with mupirocin.19
Nasal PVI may be preferred over mupirocin for long-
term prevention of S. aureus infections because it is easy to
use and it has multiple targets of action—thus, the risk of
PVI resistance among S. aureus isolates is minimal.23 29–31
PVI has been used in healthcare for years for skin antisepsis. Recently, small, single-centre studies found that
nasal PVI was associated with decreased surgical site
infection rates, and that surgical patients preferred this
product over mupirocin because it had fewer side effects
and was more pleasant.32–35 Some investigators have used
PVI at haemodialysis catheter exit sites or for catheter
care.36 37 However, no published studies have evaluated
nasal PVI for decolonising patients on haemodialysis.
Our objectives are to evaluate whether decolonising
patients’ noses with PVI will reduce rates of S. aureus BSI
among patients on haemodialysis, to qualitatively evaluate
the implementation of this intervention, and to assess
patient and HCW satisfaction with PVI. This trial will
be performed at 16 outpatient haemodialysis units affiliated with five academic medical centres. These ambulatory haemodialysis units are geographically dispersed
and care for both rural and urban patients who receive
chronic care.
We chose the stepped-wedge CRT design for multiple
reasons. First, since nasal PVI could prevent endogenous
S. aureus infection and could prevent exogenous transmission of this organism from patient to patient, individual
randomisation would not allow us to adequately assess the
full effect of this intervention. Second, units will serve as
their own controls and as controls for other units, thus
limiting selection bias and imbalance among the intervention and control units.26 Third, the staggered starting
dates can help us measure and adjust for temporal biases
such as the effect of CMS policy changes that occur during
the study period.
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Objective 2
The study team will calculate descriptive statistics for
control and intervention survey questions. They will use
a two-sample Fisher’s exact test to assess differences in
the patients’ responses to specific questions during the
control and intervention periods. The study team will use
bivariable and multivariate regression analysis to explore
associations between survey measures and covariates.
Objective 3
Investigators will read a subset of transcripts and generate
a preliminary codebook using an integrated approach to
thematic analysis that includes a priori project-specific
thematic codes, Consolidated Framework for Implementation Research constructs and inductive codes identified
during team discussions. Thereafter, the team will code
documents, then iteratively adapt the codebook, conduct
preliminary analyses, adapt the interview guide if needed
and gauge whether data saturation (ie, no new themes or
patterns emerge) has been reached. If data saturation has
not been attained or if new areas are identified, we will
perform, record and analyse additional telephone interviews. The team will document codebook changes and
the rationale for each change and will keep an audit trail.
Patient and public involvement
Neither patients nor members of the public participated
in designing this study.
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Limitations
The proposed study has three main limitations. First,
nasal PVI suppresses bacteria for only 12–24 hours.31
Thus, PVI must be reapplied before each procedure.
Second, we will not compare PVI with mupirocin.
Instead, our control group will be standard care, which
is justified because mupirocin has not been routinely
used for preventing BSI among patients on haemodialysis
due to implementation barriers. Third, PVI is considered
a novel intervention for patients on haemodialysis, and
thus, we are required to obtain informed consent from
each patient. Therefore, patients who do not consent to
using nasal PVI could transmit S. aureus to patients who
do participate in the intervention.
Significance
Nasal PVI is currently used in many hospitals to prevent
surgical site infections. Our study evaluates this product
in a new patient population. This large stepped-wedge
CRT aims to determine whether nasal PVI decreases rates
of S. aureus BSI among patients on haemodialysis, and
to collect data on barriers and facilitators to implementation. Given that PVI as widely available and inexpensive, is easy to use and implement, and does not cause
resistance, this intervention could be more generalisable
than mupirocin ointment. An effective intervention to
prevent infections among patients on haemodialysis
could improve outcomes among the 2 million people who
receive renal replacement therapy worldwide.38
Trial status
Trial is currently ongoing.
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